SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
Yuanta Securities: Maintains "buy" rating on Shanghai Fosun Pharmaceutical (02196) with a target price of HK$26.5
Zhongjin: The supply and demand situation in the paper industry is still relatively loose, and the production capacity utilization rate of cardboard and corrugated paper may see a recovery.
Executive resignation wave is a good opportunity for AI strategy restart, Evercore gives Apple Inc. (AAPL.US) an "outperform" rating.
Yuanta Securities: Maintains "buy" rating on Shanghai Fosun Pharmaceutical (02196) with a target price of HK$26.5
Zhongjin: The supply and demand situation in the paper industry is still relatively loose, and the production capacity utilization rate of cardboard and corrugated paper may see a recovery.
Executive resignation wave is a good opportunity for AI strategy restart, Evercore gives Apple Inc. (AAPL.US) an "outperform" rating.
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025
